Search For "dcgi"
Dr Reddy's launches Redyx (Remdesivir) in India for COVID-19 treatment
Updated : 5 years, 6 months ago IST
Hyderabad (Telangana) [India], September 9 (ANI): Dr Reddy's Laboratories on Wednesday announced the launch of Remdesivir under the brand name Redyx for Indian markets.
Read More
Serum Institute initiates phase 2, 3 clinical study on 1,600 volunteers fo
Updated : 5 years, 6 months ago IST
New Delhi [India], August 19 (ANI): Indian pharmaceutical giant Serum Institute of India has initiated the phase 2, 3 clinical trials to evaluate the safety and immune response of coronavirus vaccine candidate on healthy Indian adults after the pharma company got approval from Drugs Controll
Read More
COVID-19: Subject Expert Committee seeks DCGI's nod to use hepatitis injec
Updated : 5 years, 6 months ago IST
New Delhi [India], Aug 19 (ANI): The Subject Expert Committee (SEC) at the Central Drugs Standard Control Organisation (CDSCO) has recommended that the country's top drug regulator grant permission for phase 3 clinical trial using Thymosin @-1 injection 1.6 mg on moderate to severe COVID-19
Read More
Lupin launches Favipiravir in India for COVID treatment at Rs 49 per table
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], Aug 5 (ANI): Pharma major Lupin Ltd on Wednesday announced the launch of Favipiravir in India under the brand name Covihalt for treatment of mild to moderate COVID-19.
Read More
India's COVID-19 count rises to 18,03,696, sample testing crossed 2 crore
Updated : 5 years, 7 months ago IST
New Delhi [India], August 3 (ANI): With 52,972 positive cases reported in India on Monday, the COVID-19 count in the country breached the 18 lakh-mark, Union Ministry of Health and Family Welfare said. The country also crossed the two crore-mark for the COVID-19 samples tested till August
Read More
DCGI gives nod to Serum Institute to hold Phase II, III COVID vaccine tria
Updated : 5 years, 7 months ago IST
New Delhi [India], Aug 3 (ANI): The Drugs Controller General of India (DCGI) gave approval to Serum Institute of India, Pune to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India, said the Ministry of Health and Family Welfare on
Read More
DCGI nod to Serum-Oxford COVID19 vaccine for phase 2, 3 clinical trials in
Updated : 5 years, 7 months ago IST
New Delhi, [India], Aug 3 (ANI) India's top drug regulator-- Drugs Controller General of India (DCGI) has granted permission to Serum Institute of India (SII) to conduct phase 2 and 3 human clinical trials in India on the potential COVID19 vaccine, a senior government official said.
Read More
COVID-19: Health Ministry directs DCGI to ensure equitable distribution of
Updated : 5 years, 7 months ago IST
New Delhi [India], July 29 (ANI): The Union Health and Family Welfare Ministry has directed the Drugs Controller General of India (DCGI) to ensure equitable distribution of drugs across the country included as part of "investigational therapies" in clinical management protocol for COVID-19.
Read More
COVID-19: Health ministry decides not to put Itolizumab in national treatm
Updated : 5 years, 7 months ago IST
New Delhi, July 26 (ANI): Even as the Drugs Controller General of India (DCGI) has given permission to Itolizumab drug for restricted emergency use on moderate to severe COVID-19 patients, the Union Health Ministry has decided not to include the drug in the national treatment protocol for co
Read More
Domestic pharma giant SII applies to DCGI for phase 2/3 clinical trial of
Updated : 5 years, 7 months ago IST
New Delhi [India], July 25 (ANI): In a development related to the COVID-19 vaccine, the Serum Institute of India (SII) has applied to the Drugs Controller General of India (DCGI) for conducting the Phase 2/3 human clinical trials for a potential coronavirus vaccine.
Read More
Top drug regulator suspends import license of 19 firms for their COVID-19
Updated : 5 years, 7 months ago IST
New Delhi [India], July 25 (ANI): The Central Drugs Standard Control Organisation (CDSCO) has suspended the import licenses of at least 19 firms for their respective COVID-19 test kits after USFDA removed the manufacturer from their list of the product of serology test kits for coronavirus.
Read More
Cipla gets regulatory nod for launch of Ciplenza to treat mild to moderate
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], July 24 (ANI): Pharmaceutical major Cipla said on Friday it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza.
Read More